METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Dec 10, 2015
filing date -
Apr 5, 2002
priority date (Note) -
Abandoned
status (Latency Note)
![]() |
A preliminary load of PAIR data current through [] has been loaded. Any more recent PAIR data will be loaded within twenty-four hours. |
PAIR data current through []
A preliminary load of cached data will be loaded soon.
Any more recent PAIR data will be loaded within twenty-four hours.
![]() |
Next PAIR Update Scheduled on [ ] |

Importance
Loading Importance Indicators...

Calculated Rating
US Family Size
|
Non-US Coverage
|
Abstract
This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
First Claim
all claims..Other Claims data not available
Family
Loading Family data...

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Patent Owner(s)
Patent Owner | Address | |
---|---|---|
VENTANA MEDICAL SYSTEMS INC | 1910 E INNOVATION PARK DRIVE TUCSON AS 85755 |
International Classification(s)

- 2015 Application Filing Year
- G01N Class
- 11310 Applications Filed
- 8345 Patents Issued To-Date
- 73.79 % Issued To-Date
Inventor(s)
Inventor Name | Address | # of filed Patents | Total Citations |
---|---|---|---|
Bacus, Sarah S | Hinsdale, US | 31 | 601 |
# of filed Patents : 31 Total Citations : 601 | |||
Smith, Bradley L | Marblehead, US | 11 | 207 |
# of filed Patents : 11 Total Citations : 207 |
Cited Art Landscape
- No Cited Art to Display
Loading Cited Art Landscape... 

Patent Citation Ranking
- 0 Citation Count
- G01N Class
- 0 % this patent is cited more than
- 9 Age
Forward Cite Landscape
- No Forward Cites to Display
Loading Forward Cite Landscape... 

Maintenance Fees
Fee | Large entity fee | small entity fee | micro entity fee | due date |
---|---|---|---|---|
11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Sep 30, 2027 |
Fee | Large entity fee | small entity fee | micro entity fee |
---|---|---|---|
Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |
Full Text
US Patent Application No: 2017/0014,525
DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY
Abstract
The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
Description
Claims
Claims data not available

Legal Events
- No Legal Status data available.

Matter Detail

Country:
Application No:
Patent No:
Application Publication No:
Status:
Priority Date:
Filing Date:
Matter Type:
Local Registration No:
Docket No:
Secondary System Identifier (SSI):
Customer Application No:
Filing Type:
Request for Examination Date:
Parent Filing Date:
Complete Specification Date:
PCT Filing Date:
National Entry Date:
First Publication Date:
Allowance Date:
Grant Date:
Grant Publication Date:
Claims:
Independent Claims:
Law Firm:
Renewals Detail

Applicant:
Applicant ID:
Entity Size:
Renewal Status:
Renewal Base Date:
Renewal Trigger Date: